Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy.
Cardiac hypertrophy
Hypertension
Oxidative stress
Zn-candesartan
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
05 May 2023
05 May 2023
Historique:
received:
31
10
2022
revised:
25
02
2023
accepted:
09
03
2023
medline:
31
3
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
Hypertension is the most common cause of left ventricular hypertrophy, contributing to heart failure progression. Candesartan (Cand) is an angiotensin receptor antagonist widely used for hypertension treatment. Structural modifications were previously performed by our group using Zinc (ZnCand) as a strategy for improving its pharmacological properties. The measurements showed that ZnCand exerts a stronger interaction with the angiotensin II receptor, type 1 (AT
Identifiants
pubmed: 36930883
pii: S0014-2999(23)00165-6
doi: 10.1016/j.ejphar.2023.175654
pii:
doi:
Substances chimiques
Antihypertensive Agents
0
Biphenyl Compounds
0
candesartan
S8Q36MD2XX
Matrix Metalloproteinase 2
EC 3.4.24.24
Tetrazoles
0
Zinc
J41CSQ7QDS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
175654Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.